PAH deficiency is caused by pathogenic variants in the PAH gene, established as the definitive causative gene for this condition based on substantial clinical evidence. The PAH gene encodes the phenylalanine hydroxylase enzyme, and impaired function of this enzyme results in accumulation of phenylalanine in blood and tissues. Genotype-phenotype correlations in PAH deficiency exist but remain imperfect. Genotype can be predictive of responsiveness to specific pharmacological therapies. Complete loss of enzyme activity, often associated with biallelic null pathogenic variants or compound heterozygosity for severe variants, is associated with severe PAH deficiency. Any combination of two null pathogenic variants leads to severe disease. PAH deficiency is inherited in an autosomal recessive pattern, meaning individuals must inherit two pathogenic variants—one from each biological parent—to be affected. Carrier parents each carry one pathogenic variant and are typically unaffected.

PAH deficiency is recommended for inclusion in newborn screening programs as a core condition on the U.S. Recommended Uniform Screening Panel (RUSP), though actual state newborn screening panel composition varies. Early detection via newborn screening typically precedes the onset of clinical findings, enabling earlier initiation of management. As described in GeneReviews, diagnosis of PAH deficiency is addressed by guidelines from the American College of Medical Genetics and Genomics (ACMG), which supplement earlier published recommendations and address both diagnosis and clinical management considerations. Newborn screening for PAH deficiency is primarily based on measurement of phenylalanine-related markers from dried blood spots collected shortly after birth. Molecular genetic testing of the PAH gene is also part of the diagnostic evaluation and can characterize the specific pathogenic variants present, which has relevance for genotype-based therapeutic decision-making.

The management of PAH deficiency is guided by established clinical protocols and guidelines developed by the American College of Medical Genetics and Genomics, as referenced in GeneReviews. Comprehensive evaluations at the time of initial diagnosis address multiple domains relevant to disease extent and management needs. Pharmacological treatment approaches for PAH deficiency are available; GeneReviews notes that genotype can be predictive of responsiveness to specific pharmacological agents, and trials of pharmacological therapy are offered to appropriate individuals based on gene variant status. Individuals with biallelic null PAH pathogenic variants are generally not offered such trials, as their genotype predicts lower responsiveness. Dietary monitoring of phenylalanine intake is central to the management of this condition. Aspartame, an artificial sweetener present in many soft drinks, foods, and medications, is metabolized in the gastrointestinal tract to phenylalanine and aspartate, making it directly relevant to phenylalanine management in PAH deficiency. Multiple additional investigational agents hold orphan drug designation for PAH deficiency, indicating ongoing research into new therapeutic modalities including gene therapy and other approaches. Patient assistance programs from the National Organization for Rare Disorders are available for individuals with PAH deficiency and are currently accepting applications.

The prognosis of PAH deficiency is substantially influenced by the timing of diagnosis, the severity of the underlying genetic variants, and the adherence to management from birth. GeneReviews clinical descriptions indicate that individuals with PAH deficiency who receive treatment from birth may still experience a modest but measurable decrease in intellectual functioning even with careful dietary adherence. Late-diagnosed or untreated individuals historically experienced more severe intellectual disability as a predominant feature of the condition. Maternal PAH deficiency poses specific prognosis-relevant implications: elevated blood phenylalanine concentrations during pregnancy are associated with toxic effects on the developing fetus, resulting in a distinct clinical entity known as maternal PKU syndrome. The clinical course is recognized to be substantially more favorable with early detection and sustained management over the lifetime.

Numerous certified active trial records are present for phenylketonuria. GeneReviews identifies multiple therapeutic modalities currently in clinical trials or in preparation for clinical trials, including gene therapy, mRNA therapy, phenylalanine uptake receptor blockers, and dietary and supplement studies. The field of PAH deficiency research is expected to yield multiple new treatment options, as noted in GeneReviews. Active clinical trials for this condition are listed on ClinicalTrials.gov.